Pharm­ing ends deal with Or­chard; Seres con­sid­ers cost-cut­ting

Plus, news about Think Bio­science and Apel­lis:

Pharm­ing ax­es Or­chard pact: The Dutch bio­phar­ma ter­mi­nat­ed a re­search col­lab­o­ra­tion and li­cens­ing agree­ment with Or­chard Ther­a­peu­tics due to “cur­rent strat­e­gy as well as pri­or­i­ti­za­tion.” Back in 2021, Pharm­ing paid $17.5 mil­lion up­front and promised up to $189.5 mil­lion in biobucks for OTL-105, a gene ther­a­py for the rare dis­or­der hered­i­tary an­gioede­ma. Or­chard is now owned by Ky­owa Kirin. — Kyle LaHu­cik

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER